Untitled

doi:10.18632/oncotarget.v9i27

Cited by 6 publications

(2 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…9 In a Swedish cohort of cervical cancer patients, HPV16, 18, 31, 45, and 33 were the most frequently detected genotypes. 28 In this epidemiological study, we found that HPV16 (22.7%), HPV52 (15.5%), HPV58 (14.6%), HPV81 (12.9%), and HPV53 (11.0%) were the common genotypes of HPV infections in HPV-positive cervical cancer patients. Further, our epidemiological study showed that HPV53 accounted for a high proportion of infection in both HPV-positive female patients and HPV-positive cervical cancer patients.…”

Section: Discussionmentioning

confidence: 72%

Human papillomavirus genotypes and infection among women in Changzhou, China

Geng

Liu

2019

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Human papillomavirus (HPV) infection is a major cause of cervical cancer. HPV vaccine has been shown to be highly effective in preventing HPV infection, and understanding the genotypes of HPV infection can guide the utilization of HPV vaccine. This epidemiological study aimed to investigate the genotype distribution of HPV in HPV-positive female patients in Changzhou. This study enrolled HPV-positive female patients admitted at the Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University were enrolled in this study. HPV genotypes were identified via standard HPV DNA testing. The cohort comprised 5738 patients, that the predominant genotypes were HPV52 (13.4%), HPV16 (9.6%), HPV58 (8.8%), HPV81 (8.6%), and HPV53 (7.7%). HPV infection prevalence was the highest among those aged 41-45 y (16.6%), followed by those aged 31-35 y (15.1%) and 36-40 y (15.1%). In total, 46.8% of infections were found in women aged 31-45 y. The main genotypes of HPV infection upon physical examination or diagnosis of cervicitis and cervical cancer were HPV52,16, 58, 81, and 53. HPV52,16, 58, 81, and 53 are the most predominant genotypes of HPV infection. Further, HPV infection is most prevalent among women aged 31-45 y. Our findings provide experimental evidence for guiding HPV vaccination policy.

show abstract

Section: Discussionmentioning

confidence: 72%

Human papillomavirus genotypes and infection among women in Changzhou, China

Geng

Liu

2019

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…This single-arm pilot study was designed to determine the ORR of anti-PD-L1 (durvalumab) and anti-CTLA-4 (tremelimumab) in metastatic ER-positive BC and TNBC. 60 higher rates of clinical benefit were observed in TNBC. Further research is warranted in TNBC to confirm the findings.…”

Section: Dual Checkpoint Blockade Therapymentioning

confidence: 97%

<p>Combination Strategies of Checkpoint Immunotherapy in Metastatic Breast Cancer</p>

Liu¹,

Zhang²,

Ji³

et al. 2020

OTT

View full text Add to dashboard Cite

Checkpoint immunotherapy is emerging as a new therapeutic approach for metastatic breast cancer. Monotherapy of immunoagents against PD1/PD-L1 or CTLA-4 has shown little efficacy in these patients. Recently, to determine the optimal use of immunotherapy, there has been a rapid expansion in the number of clinical trials developing immunotherapy combinations. These combination therapeutic approaches can enhance various aspects of cancer immunity, such as tumor antigenicity or intratumor T cell infiltration, which provides a theoretical basis for combining them with checkpoint immunotherapy to achieve synergistic effects. Here, we review the available data and ongoing efforts to establish the safety and efficacy of immunoagents in combination with chemotherapy, radiotherapy, HER2-targeted therapy, CDK4/6 inhibitors, PARP inhibitors, and another checkpoint immunoagents.

show abstract

Sequential Ipilimumab After Chemoradiotherapy in Curative-Intent Treatment of Patients With Node-Positive Cervical Cancer

et al. 2020

View full text Add to dashboard Cite

IMPORTANCE Despite standard chemoradiotherapy (CRT), most women with lymph node (LN)-positive cervical cancer experience disease recurrence. Immunotherapy is being investigated in the up-front treatment setting.OBJECTIVES To assess the safety of sequential immunotherapy after CRT and to investigate human papillomavirus (HPV) genotype and HLA allele status on survival and programmed cell death 1 (PD-1) expression before and after CRT and sequential immunotherapy. DESIGN, SETTING, AND PARTICIPANTS This prospective phase 1 trial conducted in 29Gynecology Oncology Cooperative Group member institutions enrolled participants from December 18, 2012, to August 31, 2016, with a 14.8-month median follow-up and translational end points. Thirty-four women with International Federation of Gynecology and Obstetrics stage IB2 to IVA cervical cancer with positive pelvic LNs, para-aortic LNs, or both were enrolled; 13 did not receive ipilimumab and were excluded from the analysis. Data were analyzed from January 21 to April 4, 2018.INTERVENTIONS Treatment consisted of 6 weekly doses of cisplatin, 40 mg/m 2 , concurrent with radiotherapy. After completion of chemotherapy, sequential ipilimumab was given every 21 days for 4 doses. Two dosage levels of ipilimumab, 3 mg/kg and 10 mg/kg, were studied to identify the maximum tolerated dose. MAIN OUTCOMES AND MEASURESThe primary end point was safety, and the secondary end points were overall survival and progression-free survival. Exploratory end points included HPV genotype, HLA allele status, and PD-1 expression measured in peripheral blood. RESULTSThe median age of the 32 participants included in the intent-to-treat analysis was 50 (range, 26-61) years, and 22 patients (69%) were white. Of the 21 patients who received ipilimumab, all had positive pelvic LN, and 6 (29%) had positive para-aortic LNs. All patients completed CRT, and of the 21 patients who received at least 2 cycles of ipilimumab, 18 (86%) completed 4 cycles of ipilimumab, and 3 (14%) completed 2 cycles. The maximum tolerated dose was 10 mg/kg. Two of the 21 patients (9.5%) who received ipilimumab had self-limiting grade 3 toxic effects (lipase increase; dermatitis). The 12-month overall survival was 90%, and progression-free survival was 81%. Human papillomavirus genotype and HLA subtype were not associated with progression-free survival or overall survival. T cells expressing PD-1 increased after CRT, and levels were sustained with ipilimumab.CONCLUSIONS AND RELEVANCE This study's findings suggest that the use of immunotherapy after CRT for curative-intent treatment of patients with cervical cancer is tolerable and effective. The results indicated that PD-1 was upregulated after CRT and sustained with sequential ipilimumab therapy. These immune findings may help guide future therapies to harness the activated T-cell phenotype in patients with node-positive cervical cancer.

show abstract

Untitled

Cited by 6 publications

References 66 publications

Human papillomavirus genotypes and infection among women in Changzhou, China

Human papillomavirus genotypes and infection among women in Changzhou, China

<p>Combination Strategies of Checkpoint Immunotherapy in Metastatic Breast Cancer</p>

Sequential Ipilimumab After Chemoradiotherapy in Curative-Intent Treatment of Patients With Node-Positive Cervical Cancer

Contact Info

Product

Resources

About